83 related articles for article (PubMed ID: 8782017)
1. Effect of antiretroviral therapy on plasma HIV RNA.
Saag MS
J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
[No Abstract] [Full Text] [Related]
2. HIV-1 and HAART: a time to cure, a time to kill.
Saag MS; Kilby JM
Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
[No Abstract] [Full Text] [Related]
3. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
Marcello A; Giacca M
Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
[No Abstract] [Full Text] [Related]
4. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
5. Virological markers of progression: a UK experience.
Loveday C
J Biol Regul Homeost Agents; 1995; 9(3):100-4. PubMed ID: 8782016
[No Abstract] [Full Text] [Related]
6. [New biological monitoring of HIV infection].
Morand-Joubert L
Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
[No Abstract] [Full Text] [Related]
7. Control of HIV despite the discontinuation of antiretroviral therapy.
Lisziewicz J; Rosenberg E; Lieberman J; Jessen H; Lopalco L; Siliciano R; Walker B; Lori F
N Engl J Med; 1999 May; 340(21):1683-4. PubMed ID: 10348681
[No Abstract] [Full Text] [Related]
8. Latent reservoirs of HIV infection: flushing with IL-2?
Cooper DA; Emery S
Nat Med; 1999 Jun; 5(6):611-2. PubMed ID: 10371491
[No Abstract] [Full Text] [Related]
9. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
[TBL] [Abstract][Full Text] [Related]
10. Ongoing HIV dissemination during HAART.
Grossman Z; Polis M; Feinberg MB; Grossman Z; Levi I; Jankelevich S; Yarchoan R; Boon J; de Wolf F; Lange JM; Goudsmit J; Dimitrov DS; Paul WE
Nat Med; 1999 Oct; 5(10):1099-104. PubMed ID: 10502799
[No Abstract] [Full Text] [Related]
11. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
[TBL] [Abstract][Full Text] [Related]
12. [Surrogate endpoints in clinical studies exemplified by HIV infection].
Furrer H
Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1079-88. PubMed ID: 9691341
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
[TBL] [Abstract][Full Text] [Related]
14. The emerging race to cure HIV infections.
Cohen J
Science; 2011 May; 332(6031):784-5, 787-9. PubMed ID: 21566173
[No Abstract] [Full Text] [Related]
15. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
Romano L; Venturi G; Catucci M; De Milito A; Valensin PE; Zazzi M
J Infect Dis; 1999 Feb; 179(2):361-6. PubMed ID: 9878019
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.
Kim HN; Tabet SR; Corey L; Celum CL
Vaccine; 2006 Jan; 24(4):532-9. PubMed ID: 16242816
[TBL] [Abstract][Full Text] [Related]
18. HIV biological phenotype: prognosis marker for transmission, disease progression and therapy.
Fenyö EM
J Biol Regul Homeost Agents; 1995; 9(3):88-90. PubMed ID: 8782013
[No Abstract] [Full Text] [Related]
19. [Resistance investigations during HIV-therapy is necessary].
Schattenfroh S
Dtsch Med Wochenschr; 1998 Feb; 123(7):A7. PubMed ID: 9505940
[No Abstract] [Full Text] [Related]
20. [Detection of the viral load and its use as a virological marker in the follow-up of HIV-1-positive patients].
Hodara VL; Monticelli A; Benetucci J; Lasala M; Jauregui Rueda H; Libonatti O; García Messina O; Reboredo G; Bogdanowicz E; Bases O; Pampuro S; Salomón H
Rev Argent Microbiol; 1998; 30(1):1-7. PubMed ID: 9629601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
